A study of fostamatinib in subjects with impaired hepatic (liver) function

Exclusion Criteria

• - Subjects who have received any medications known to alter drug absorption or elimination within 30 days of first dose.
• - Subjects who smoke more than 10 cigarettes or equivalent per day
• - Absolute neutrophil count <2500/mm3
• - Abnormal vital signs, additional systemic disease (eg, cardiac, or renal disease) or abnormal laboratory findings that are judged to be clinically significant by the investigator
• - Healthy volunteers only: use of prescribed medications within 2 weeks of first dose or use of non-prescribed medications within 1 week of first dose
• - Hepatic subjects only: fluctuating or rapidly deteriorating hepatic function